younes Oujidi
Berkane, 9999, Morocco
Completed
NCT Number: NCT05008016
Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.
Background:
Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection .
Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .
Completed
Looking for future studies?
Notify MeKey information
Age range
15 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
Our objective is to assess the relationship between Procalcitonin and 30-day mortality in patients admitted to the resuscitation department of the Mohammed VI University Hospital Center, Oujda, Morocco, infected by the SARS COV 2 Virus .
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of SARS COV2 infection needed admission in ICU .
Exclusion criteria
- patient under 15 ans
Treatment and study plan
Primary outcomes
-
Procalcitonin is a marker of mortality
Time frame: through study completion, an average of 8 mounths
as a cutoff 0.5 ng/ml Procalcitonin could be used as mortality factors
Sponsors and collaborators
Lead sponsor
Mohammed VI University Hospital
Other
Registry information
Official study title
Procalcitonin Level and the High Risk of Mortality in 30 Days , in Critically Ill Patients Infected by SARS-CoV-2, Experience of a North African Hospital University , Cases Series.
Important dates
- Study start
- 2020
- Primary completion
- 2020
- Study completion
- 2021
- First posted
- Aug 17, 2021
- Registry last updated
- Aug 17, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.